Increasing prevalence of Alzheimer’s disease is fueling the demand for Alzheimer’s drugs which in turn is driving the global Alzheimer’s drugs market, says Fortune Business Insights in a report, titled “Alzheimer’s Drugs Market”, Size, Share and Global Trend By Drug Class (Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Antagonist, Combination Drugs, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography Forecast till 2026.
Rising R&D activities by pharmaceutical companies and research institutes for Alzheimer effective therapy is expected to boost the global Alzheimer’s drugs market.
The healthcare industry is of the biggest industry in the world comprising of different segments including biotechnology, pharmaceutical, healthcare equipment, diagnostic devices, healthcare services, and others. Stakeholders in the healthcare industry are witnessing a shift from traditional practices towards a novel way of diagnostics due to the growing application of the Internet of Things (IoT) in this sector. Furthermore, growing consumer demand for personalized and low-cost devices is positively influencing the industry growth, resulting in innovation and technological development of the products, diagnostic methods, and treatment.
Request a Sample Copy of the Research Report:
https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/alzheimers-drugs-market-101033
The healthcare industry is of the biggest industry in the world comprising of different segments including biotechnology, pharmaceutical, healthcare equipment, diagnostic devices, healthcare services, and others. Stakeholders in the healthcare industry are witnessing a shift from traditional practices towards a novel way of diagnostics due to the growing application of the Internet of Things (IoT) in this sector. Furthermore, growing consumer demand for personalized and low-cost devices is positively influencing the industry growth, resulting in innovation and technological development of the products, diagnostic methods, and treatment.
The Collaboration Between Eli Lilly and AC Immune Will Aid Growth
Eli Lilly and Company and AC Immune SA announced their partnership agreement to research and develop tau aggregation inhibitor small molecules for the potential treatment of Alzheimer’s disease (AD) and other neurodegenerative diseases. The collaboration between the two companies is predicted to benefit Alzheimer’s drugs revenue owing to the Morphomer™ platform technology which will offer commercial capabilities in central nervous system disorders along with AC Immune’s lead molecule, ACI-3024. Furthermore, the development of digital tools for Alzheimer’s disease and dementia is also expected to contribute to the global Alzheimer’s drugs growth. For instance, the Alzheimer’s Drug Discovery Foundation (ADDF), announced a new initiative -Diagnostics Accelerator program that aims to track the development of digital tools for Alzheimer’s disease and dementia.
For more information in the analysis of this report, visit:https://www.fortunebusinessinsights.com/industry-reports/alzheimers-drugs-market-101033
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245